V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017581 | 160018319 | 1.65 | 106.6 | Curative (C) | 2018-02-07 | 2018-02-13 | LANREOTIDE | 02 | N | IFOSFAMIDE | 101161754 |
| 160017582 | 160018320 | 1.55 | 110 | null | 2019-09-07 | 2019-09-07 | CYCLOPHOSPHAMIDE + VINORELBINE | 01 | null | EW EUROEWING 99 : VACTC | 101358586 |
| 160017589 | 160018321 | 1.79 | 59.1 | Curative (C) | 2016-08-19 | 2016-08-20 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | null | IFOSFAMIDE | 101010455 |
| 160017598 | 160018322 | 1.56 | 54.75 | Adjuvant (A) | 2019-05-16 | 2019-05-19 | Gemcitabine 1000mg/m2 D1 8 15 | Y | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101167241 |
| 160017604 | 160018323 | 0 | 121.4 | null | 2018-09-28 | 2018-10-12 | Ifosfamide | 01 | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 101663511 |
| 160017610 | 160018324 | 1.72 | 68.5 | null | 2019-02-08 | 2019-02-19 | NB HRNBL-1 BUMEL MAT | N | null | LANREOTIDE | 100706943 |
| 160000341 | 160018325 | 1.71 | 90 | Curative (C) | 2019-10-15 | 2019-10-25 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100944148 |
| 160001486 | 160018326 | 0 | 58.9 | Palliative (P) | 2020-03-02 | 2020-03-31 | LANREOTIDE | 02 | N | EW EUROEWING 2012 ARM B VC | 101068815 |
| 160001867 | 160018327 | null | null | Palliative (P) | null | 2018-09-12 | Gemcitabine day 1&8 | 2 | N | RITUXIMAB | 100608098 |
| 160002009 | 160018328 | 1.67 | 86 | null | 2020-05-10 | 2020-05-25 | Eribulin | 02 | null | NOT MATCHED | 100169851 |
| 160003704 | 160018330 | 1.78 | 47.4 | Palliative (P) | 2016-05-16 | 2016-11-10 | Ifosfamide | 02 | null | LANREOTIDE | 101329324 |
| 160003966 | 160018331 | null | null | null | null | 2018-04-08 | Doxorubicin + Ifosfamide | 02 | null | REGORAFENIB | 100428369 |
| 160005199 | 160018333 | 1.7 | 104 | Curative (C) | 2019-05-29 | 2019-10-07 | Cyclophosphamide + Topotecan | 02 | null | CAPECITABINE + CARBOPLATIN | 100797738 |
| 160006388 | 160018334 | 1.74 | 92.9 | null | 2016-03-08 | 2016-10-20 | IVADo | null | null | NOT MATCHED | 101297123 |
| 160006389 | 160018335 | 0 | 86 | Palliative (P) | 2020-03-28 | 2020-03-29 | Olaparib | 01 | N | EW REL REECUR GEMCITABINE/DOCETAXEL | 100953709 |
| 160007240 | 160018336 | 1.49 | null | null | 2017-02-05 | 2017-05-08 | VAC | N | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101524382 |
| 160007389 | 160018337 | 0 | 15.1 | Palliative (P) | 2016-12-28 | 2017-01-12 | VAI (Ifos 3g/m2) | 02 | N | CEDIRANIB | 100844374 |
| 160008630 | 160018339 | 1.86 | 58 | Neo-adjuvant (N) | 2022-02-09 | 2022-02-09 | EW EuroEwing 2012 Arm B VDC | 02 | N | DINUTUXIMAB BETA | 100288187 |
| 160008800 | 160018340 | 1.81 | 100.4 | Palliative (P) | 2017-11-06 | 2017-11-06 | IVA | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 100275941 |
| 160008830 | 160018341 | null | 86.2 | Palliative (P) | 2020-05-05 | 2020-05-10 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | EURO-EWING | 100249825 |
| 160008933 | 160018342 | 1.59 | 69.8 | Curative (C) | 2017-07-13 | 2017-07-13 | Ifosfamide | 02 | N | TRIAL | 101078869 |
| 160008964 | 160018343 | 1.61 | 72.4 | 03 | 2021-12-05 | 2022-01-12 | Olaratumab | 02 | N | OLAPARIB | 101078776 |
| 160009395 | 160018344 | 1.66 | 77.1 | null | 2019-09-07 | 2019-09-07 | Ifosfamide + Liposomal Doxorubicin | 02 | null | OLARATUMAB | 100169012 |
| 160009476 | 160018345 | 0 | 51.6 | null | 2019-01-24 | 2019-01-27 | NB Relapsed CCLG guidelines TVD | 01 | null | CONFIRM TRIAL | 100784347 |
| 160009742 | 160018346 | 1.49 | 58.3 | Palliative (P) | 2017-03-09 | 2018-02-23 | Carboplatin + Vinorelbine IV | 01 | N | GEMCITABINE | 101683016 |
| 160010151 | 160018349 | 1.77 | 78.6 | null | 2018-03-02 | 2018-09-15 | CARBOPLATIN + ETOPOSIDE | 02 | null | IVA | 100237670 |
| 160010269 | 160018350 | 1.63 | 19.5 | null | null | 2019-08-13 | EW EuroEwing 2012 Arm B IE | 02 | null | DARATUMUMAB | 100684796 |
| 160010408 | 160018352 | 1.5 | 75 | Curative (C) | 2017-09-08 | 2017-09-09 | GC Int Guide Excranial GermCell JEB | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101861151 |
| 160010475 | 160018353 | 0 | 62.1 | Curative (C) | 2019-03-16 | 2019-03-18 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | NOT MATCHED | 100519514 |
| 160010801 | 160018356 | 1.8 | 58.4 | Curative (C) | 2017-05-28 | 2017-06-04 | EW EuroEwing 2012 Arm B IE | 02 | N | NB BEACON DINUTUXIMAB + TEMOZOLOMIDE + TOPOTECAN | 100508709 |
| 160010938 | 160018357 | 1.55 | 84 | Palliative (P) | 2019-06-22 | 2019-07-25 | Olaratumab | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101163903 |
| 160011166 | 160018358 | 1.76 | 71 | null | 2020-05-09 | 2020-06-06 | EW EuroEwing 2012 Arm B IE | 02 | null | CARBOPLATIN + VINORELBINE | 101542759 |
| 160011320 | 160018359 | 1.62 | 87.35 | null | 2018-10-28 | 2018-11-13 | Doxorubicin + Ifosfamide | 02 | N | CAV | 101746287 |
| 160011782 | 160018361 | null | null | null | 2017-09-11 | 2018-04-02 | Doxorubicin + Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101612656 |
| 160011895 | 160018362 | 0.89 | 70.85 | Curative (C) | 2019-04-09 | 2019-08-24 | EW EuroEwing 2012 Arm B VC | 02 | N | NIRAPARIB | 101049355 |
| 160011962 | 160018363 | 1.58 | 68.85 | Palliative (P) | 2018-08-05 | 2018-08-07 | IVA | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100667890 |
| 160012068 | 160018364 | 0 | 14.6 | Palliative (P) | 2019-03-20 | 2019-12-02 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101598329 |
| 160012366 | 160018365 | 1.86 | 95 | Curative (C) | 2017-12-07 | 2018-01-18 | Etoposide + Ifosfamide + HD Mtx | 02 | N | DACARBAZINE | 100358644 |
| 160012860 | 160018367 | null | 73.6 | null | 2019-10-16 | 2019-12-23 | EW EuroEwing 2012 Arm B VC | 02 | null | TRIAL | 100453526 |
| 160013237 | 160018368 | 1.66 | 61.8 | Not known (9) | 2018-07-08 | 2018-07-08 | GEMCITABINE | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 100446913 |
| 160013461 | 160018369 | 0 | 71.1 | Palliative (P) | 2019-08-09 | 2019-11-08 | VINCRISTINE | 02 | Y | CYCLOPHOSPHAMIDE + TOPOTECAN | 101452805 |
| 160013479 | 160018370 | 1.63 | 58.6 | Palliative (P) | 2020-11-13 | 2021-02-07 | Olaratumab | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100037693 |
| 160014131 | 160018371 | null | 85.9 | Neo-adjuvant (N) | 2019-02-13 | 2019-02-22 | Cyclophosphamide + Vincristine | 02 | null | CAPECITABINE + OXALIPLATIN | 101216764 |
| 160014432 | 160018373 | null | 81.2 | Neo-adjuvant (N) | 2018-07-14 | 2018-07-22 | IDELALISIB | 02 | null | ICON8B TRIAL | 101285374 |
| 160014575 | 160018374 | 0 | 71.3 | Palliative (P) | 2020-12-19 | 2020-12-26 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | NOT MATCHED | 100932501 |
| 160014891 | 160018375 | 1.66 | 76.65 | Adjuvant (A) | 2017-06-07 | 2017-12-16 | Cisplatin | 02 | N | GEMCITABINE | 101812067 |
| 160015510 | 160018376 | 0 | 44.5 | null | 2021-04-08 | 2021-04-21 | Temozolomide 200mg/m2 | null | null | ETOP 13-18 BEAT-MESO TRIAL | 101243872 |
| 160015547 | 160018377 | 1.57 | 70.2 | 03 | 2018-12-24 | 2018-12-27 | GEMCITABINE | 02 | N | GEMCARBO | 101260596 |
| 160015614 | 160018378 | 0 | 14.6 | Curative (C) | 2014-06-12 | 2014-11-03 | GEMCITABINE | 01 | N | STS RHABDO RMS 2005 VIN CYCLO | 100093550 |
| 160016294 | 160018380 | 1.83 | 108.5 | null | 2018-12-05 | 2018-12-06 | CONFIRM TRIAL | 99 | null | FLAIR TRIAL | 100012257 |